✦ LIBER ✦

TP53 family members and human cancers

✍ Scribed by Jean Bénard; Setha Douc-Rasy; Jean-Charles Ahomadegbe

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 179 KB
Volume: 21
Category: Article
ISSN: 1059-7794
DOI: 10.1002/humu.10172

No coin nor oath required. For personal study only.

✦ Synopsis

Based on gene sequence homologies, a p53 (TP53) gene family become apparent with the addition of the most recently identified p63 (TP73L; formerly TP63) and p73 (TP73) genes to the already known p53. The p53 gene encodes for a unique protein eliciting well-known tumor suppressor gene (TSG) properties that mediate cellular response to DNA damage, e.g., cell cycle arrest or apoptosis. In contrast, both homologues specify an array of isoforms different in their N- and C-terminal domains. Transactivating isoforms, such as TAp63/p73, show TSG properties similar to p53, while isoforms lacking N-terminal transactivating domain such as DeltaNp63/p73, induce a functional block against p53 as well as TAp63/p73 activities. Both p63/p73 types of isoforms are involved in development: p63 is critical for epithelial stem cell renewal and epithelial homeostasis, and p73 is involved in neurogenesis and natural immune response. These facts support interdependent functions for the p53 family members, which appear linked together in a complex and tight regulation network to fulfill cellular functions related to DNA damage and tissue homeostasis maintenance. The lack of p63/p73 mutations in human cancers rule out a typical TSG role for either of the p53 homologues. Nonetheless, p63 and p73 genes seem strongly involved in malignancy acquisition and maintenance process because of: 1) their tissue identities, and 2) their close interplay activities within the p53 family members, and primarily through the negative regulatory role played by DeltaNp63/p73 isoforms for cell death control and differentiation.

📜 SIMILAR VOLUMES

TP53 mutations in human skin cancers

✍ Giuseppina Giglia-Mari; Alain Sarasin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB

The p53 gene (TP53) is mutated in numerous human cancers. We have used it as a molecular target to characterize the induction of mutations in human skin cancers. About 50% of all skin cancers in normal individuals exhibit p53 mutations. This frequency rises to 90% in skin cancers of patients with th

Disrupting TP53 in mouse models of human

Disrupting TP53 in mouse models of human cancers

✍ John M. Parant; Guillermina Lozano 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

Manipulation of the mouse genome allows emulation of the genetic defects that give rise to human cancers and evaluation of the cooperating nature of different mutations in the transformation of distinct cell types. Here we review the generation of mice with specific missense mutations in p53 (TP53)

TP53 and breast cancer

✍ Anne-Lise Børresen-Dale 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB

TP53 and ovarian cancer

✍ Monique Schuijer; Els M.J.J. Berns 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB

Ovarian cancer represents the fourth most frequent type of cancer among females and is the leading cause of death from gynecological cancer in the western world. This review describes gene alterations in ovarian cancer. Specific emphasis is placed on genetic alterations and the prevalence of TP53 (p

TP53 mutations in familial breast cancer

TP53 mutations in familial breast cancer: Functional aspects

✍ Milena Gasco; Isik G Yulug; Tim Crook 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

Mutation in p53 (TP53) remains one of the most commonly described genetic events in human neoplasia. The occurrence of mutations is somewhat less common in sporadic breast carcinomas than in other cancers, with an overall frequency of about 20%. There is, however, evidence that p53 is mutated at a s

No germline TP53 mutations detected in f

No germline TP53 mutations detected in familial and bilateral testicular cancer

✍ Ketil Heimdal; Ragnhild A. Lothe; Sigrid Lystad; Ruth Holm; Sophie D. Fosså; Pro 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 448 KB

Mutations in the TP53 gene are considered to be among the most common genetic alterations in human cancers. Both somatic and germline mutations have been found. Using polymerase chain reaction (PCR). constant denaturant gel electrophoresis (CDGE), and denaturing gradient gel electrophoresis (DGGE),